journal
MENU ▼
Read by QxMD icon Read
search

Therapeutic Advances in Neurological Disorders

journal
https://www.readbyqxmd.com/read/28670343/differential-diagnosis-of-neuromyelitis-optica-spectrum-disorders
#1
REVIEW
Sung-Min Kim, Seong-Joon Kim, Haeng Jin Lee, Hiroshi Kuroda, Jacqueline Palace, Kazuo Fujihara
Neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory disorder of the central nervous system (CNS) mostly manifesting as optic neuritis and/or myelitis, which are frequently recurrent/bilateral or longitudinally extensive, respectively. As the autoantibody to aquaporin-4 (AQP4-Ab) can mediate the pathogenesis of NMOSD, testing for the AQP4-Ab in serum of patients can play a crucial role in diagnosing NMOSD. Nevertheless, the differential diagnosis of NMOSD in clinical practice is often challenging despite the phenotypical and serological characteristics of the disease because: (1) diverse diseases with autoimmune, vascular, infectious, or neoplastic etiologies can mimic these phenotypes of NMOSD; (2) patients with NMOSD may only have limited clinical manifestations, especially in their early disease stages; (3) test results for AQP4-Ab can be affected by several factors such as assay methods, serologic status, disease stages, or types of treatment; (4) some patients with NMOSD do not have AQP4-Ab; and (5) test results for the AQP4-Ab may not be readily available for the acute management of patients...
July 2017: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/28607577/mri-in-the-assessment-and-monitoring-of-multiple-sclerosis-an-update-on-best-practice
#2
REVIEW
Ulrike W Kaunzner, Susan A Gauthier
Magnetic resonance imaging (MRI) has developed into the most important tool for the diagnosis and monitoring of multiple sclerosis (MS). Its high sensitivity for the evaluation of inflammatory and neurodegenerative processes in the brain and spinal cord has made it the most commonly used technique for the evaluation of patients with MS. Moreover, MRI has become a powerful tool for treatment monitoring, safety assessment as well as for the prognostication of disease progression. Clinically, the use of MRI has increased in the past couple decades as a result of improved technology and increased availability that now extends well beyond academic centers...
June 2017: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/28529545/under-representation-of-women-in-stroke-randomized-controlled-trials-inadvertent-selection-bias-leading-to-suboptimal-conclusions
#3
Georgios Tsivgoulis, Aristeidis H Katsanos, Valeria Caso
No abstract text is available yet for this article.
May 2017: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/28529544/complementary-and-alternative-interventions-for-fatigue-management-after-traumatic-brain-injury-a-systematic-review
#4
Gang-Zhu Xu, Yan-Feng Li, Mao-De Wang, Dong-Yuan Cao
BACKGROUND: We systematically reviewed randomized controlled trials (RCTs) of complementary and alternative interventions for fatigue after traumatic brain injury (TBI). METHODS: We searched multiple online sources including ClinicalTrials.gov, the Cochrane Library database, MEDLINE, CINAHL, Embase, the Web of Science, AMED, PsychINFO, Toxline, ProQuest Digital Dissertations, PEDro, PsycBite, and the World Health Organization (WHO) trial registry, in addition to hand searching of grey literature...
May 2017: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/28507605/diclofenac-potassium-for-oral-solution-cambia-%C3%A2-in-the-acute-management-of-a-migraine-attack-clinical-evidence-and-practical-experience
#5
REVIEW
Shivang Joshi, Alan M Rapoport
Migraine headache affects about 12% of Western populations and is the third most common disease worldwide (sixth in terms of disability). In 1993, triptans were introduced in the United States as a new treatment for managing migraine attacks, but their use is limited by lack of response and safety concerns in some patients. Treatment options for patients with migraine who fail or cannot tolerate triptans include switching to another medication or adding an adjunctive medication. Desirable characteristics reported by patients for acute treatment of migraine attacks include complete pain relief, fast onset of action, and no pain recurrence...
April 2017: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/28507604/health-related-quality-of-life-outcomes-from-botulinum-toxin-treatment-in-hemifacial-spasm
#6
Daniel Weiss, Justine Sturm, Leonhard Hieber, Axel Börtlein, Ingo Mayr, Matthias Appy, Benedicta Kühnler, Joachim Buchthal, Christian Dippon, Guy Arnold, Tobias Wächter
BACKGROUND: Although botulinum neurotoxin (BoNT) injections may alleviate involuntary muscle contractions in hemifacial spasm substantially, it is less clear whether the motor effect would translate into improvements of health-related quality of life (HR-QoL). METHODS: In this open-label clinical observational study, we characterized outcomes on HR-QoL in terms of the EuroQol (EQ-5D-5L) from BoNT in a prospective cohort of patients with hemifacial spasm (n = 73)...
April 2017: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/28507603/fingolimod-initiation-in-multiple-sclerosis-patients-is-associated-with-potential-beneficial-cardiovascular-autonomic-effects
#7
Max J Hilz, Ruihao Wang, Carmen de Rojas Leal, Mao Liu, Francesca Canavese, Sankanika Roy, Katharina M Hösl, Klemens Winder, De-Hyung Lee, Ralf A Linker
BACKGROUND: Fingolimod slows heart rate (HR) due to vagomimetic effects and might cause additional cardiovascular autonomic changes. While the time course of HR changes is well described, the extent and course of cardiovascular autonomic changes upon fingolimod initiation has not yet been evaluated. This study, therefore, intended to assess cardiovascular autonomic changes during the first 6 h after fingolimod initiation. METHODS: In 21 patients with relapsing-remitting multiple sclerosis (RRMS), we recorded respiration (RESP), electrocardiographic RR interval (RRI), systolic and diastolic blood pressure (BPsys, BPdia) at rest, before and 0...
April 2017: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/28344656/levodopa-carbidopa-enteral-suspension-in-advanced-parkinson-s-disease-clinical-evidence-and-experience
#8
REVIEW
Johan Virhammar, Dag Nyholm
The duration of action of oral levodopa becomes shorter as Parkinson's disease (PD) progresses. Patients with advanced PD may develop potentially disabling motor fluctuations and abnormal involuntary movement (dyskinesia), which cannot be managed with optimized oral or transdermal PD medications. The progressively worsening symptoms can have a substantial impact on the patient quality of life (QoL). Levodopa-carbidopa intestinal gel (LCIG) is delivered continuously via a percutaneous endoscopic gastrostomy with a jejunal extension (PEG-J)...
March 2017: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/28344655/interactions-among-cox-2-gpiiia-and-p2y1-variants-are-associated-with-aspirin-responsiveness-and-adverse-events-in-patients-with-ischemic-stroke
#9
Xingyang Yi, Zhao Han, Qiang Zhou, Jing Lin, Chun Wang
BACKGROUND: The effect of gene variants and their interactions on response to aspirin and clinical adverse outcomes after an acute ischemic stroke (IS) is not fully understood. The aim of this study was to investigate the association of aspirin-relevant gene variants and their interactions with clinical adverse outcomes in IS patients taking aspirin. METHODS: A total of 14 variants from six genes encoding COX enzymes (COX-1, COX-2), platelet membrane receptors (TXAS1, P2Y1, P2Y12) and glycoprotein receptor (GPIIIa) were examined in 850 acute IS patients...
March 2017: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/28344654/endovascular-thrombectomy-with-or-without-systemic-thrombolysis
#10
Georgios Tsivgoulis, Aristeidis H Katsanos, Dimitris Mavridis, Anne W Alexandrov, Georgios Magoufis, Adam Arthur, Valeria Caso, Peter D Schellinger, Andrei V Alexandrov
OBJECTIVES: Current recommendations advocate that pretreatment with intravenous thrombolysis (IVT) should first be offered to all eligible patients with emergent large vessel occlusion (ELVO) before an endovascular thrombectomy (ET) procedure. However, there are observational data that question the safety and efficacy of IVT pretreatment in patients with ELVO. METHODS: We performed a meta-analysis of the included subgroups from ET randomized controlled trials (RCTs) to evaluate the comparative efficacy between direct ET without IVT pretreatment and bridging therapy (IVT and ET) in patients with ELVO...
March 2017: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/28382111/emerging-strategies-in-the-management-of-essential-tremor
#11
REVIEW
Peter Hedera
Currently available therapies for essential tremor (ET) provide sufficient control only for less than a half of patients and many unmet needs exist. This is in part due to the empiric nature of existing treatment options and persisting uncertainties about the pathogenesis of ET. The emerging concept of ET as a possible neurodegenerative disorder, better understanding of associated biochemical changes, including alterations in the γ-aminobutyric acid (GABA)-ergic system and gap junctions, and the identification of the role of the leucine-rich repeat and immunoglobulin-like domain-containing 1 (LINGO-1) gene in ET pathogenesis suggest new avenues for more targeted therapies...
February 2017: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/28382110/botulinum-toxin-in-the-management-of-chronic-migraine-clinical-evidence-and-experience
#12
REVIEW
Claus M Escher, Lejla Paracka, Dirk Dressler, Katja Kollewe
Chronic migraine (CM) is a severely disabling neurological condition characterized by episodes of pulsating unilateral or bilateral headache. The United States Food and Drug Administration (FDA) approved onabotulinumtoxinA (Botox(®)) for the prophylactic treatment of CM in 2010. It has been shown that onabotulinumtoxinA is effective in the reduction of headache frequency and severity in patients with CM. Treatment is well tolerated by the patients. This review reports on the history of botulinum neurotoxin (BoNT) in CM and presents the current clinical evidence for the use of onabotulinumtoxinA in the treatment of CM...
February 2017: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/28382109/the-efficacy-of-lacosamide-as-monotherapy-and-adjunctive-therapy-in-focal-epilepsy-and-its-use-in-status-epilepticus-clinical-trial-evidence-and-experience
#13
REVIEW
Sebastian Bauer, Laurent M Willems, Esther Paule, Christine Petschow, Johann Philipp Zöllner, Felix Rosenow, Adam Strzelczyk
Lacosamide (LCM) is approved for anticonvulsive treatment in focal epilepsy and exhibits its function through the slow inactivation of voltage-gated sodium channels (VGSCs). LCM shows comparable efficacy with other antiepileptic drugs (AEDs) licensed in the last decade: in three randomized placebo-controlled trials, significant median seizure reduction rates of 35.2% for 200 mg/day, 36.4-39% for 400 mg/day and 37.8-40% for 600 mg/day were reported. Likewise, 50% responder rates were 38.3-41.1% for 400 mg/day and 38...
February 2017: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/28382108/two-years-long-term-follow-up-in-chronic-inflammatory-demyelinating-polyradiculoneuropathy-efficacy-of-intravenous-immunoglobulin-treatment
#14
Gisa Ellrichmann, Ralf Gold, Ilya Ayzenberg, Min-Suk Yoon, Christiane Schneider-Gold
BACKGROUND: Administration of intravenous immunoglobulins (IVIgs) is established for long-term treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Prevention of secondary axonal loss going along with permanent clinical disability and muscular atrophy is a major aim in CIDP therapy. To assess long-term clinical efficacy of IVIg treatment despite heterogenous disease course and variable complaints reported by the patients, long-term electrophysiological monitoring was performed for systematic evaluation of therapeutic efficacy of IVIg...
February 2017: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/28382107/tetrabenazine-in-treatment-of-hyperkinetic-movement-disorders-an-observational-study
#15
Rita Miguel, Marcelo D Mendonça, Raquel Barbosa, Filipa Ladeira, Tânia Lampreia, José Vale, Paulo Bugalho
BACKGROUND: Tetrabenazine (TBZ) is commonly used in hyperkinetic movement disorders. In this retrospective study, we aimed to assess the TBZ effectiveness and adverse events (AEs) in Huntington disease (HD), vascular chorea, tics, dystonia, tardive oromandibular (OM) dyskinesia and other tardive syndromes (TS). METHODS: Qualitative analysis of clinical response was used to estimate TBZ effectiveness. TBZ-associated AE frequency and subsequent discontinuation rate were used to estimate tolerability; the tolerability profile was measured through the TBZ minimal dose and exposure time required to elicit AEs...
February 2017: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/28450897/plasma-exchange-as-a-cost-effective-option-for-treating-guillain-barr%C3%A3-syndrome
#16
Eric J Buenz, Gareth J Parry, Annemarei Ranta
No abstract text is available yet for this article.
January 2017: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/28450896/daclizumab-high-yield-process-in-the-treatment-of-relapsing-remitting-multiple-sclerosis
#17
REVIEW
Jana Lizrova Preiningerova, Marta Vachova
Daclizumab is a humanized monoclonal antibody that binds to the α subunit (CD25) of the interleukin-2 receptor and favorably modulates the immune environment in multiple sclerosis (MS). Blockage of CD25, among other effects, causes expansion and enhanced function of regulatory CD56(bright) natural killer cells, which seems to be the leading mechanism of action in MS. Phase II and III clinical trials have demonstrated that monthly subcutaneous injections of daclizumab high yield process (DAC HYP) 150 mg in patients with relapsing MS led to a significant reduction of annualized relapse rate and decreased number of contrast-enhanced lesions on brain magnetic resonance imaging...
January 2017: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/28450895/targeting-b-cells-in-relapsing-remitting-multiple-sclerosis-from-pathophysiology-to-optimal-clinical-management
#18
REVIEW
Stefan Bittner, Tobias Ruck, Heinz Wiendl, Oliver M Grauer, Sven G Meuth
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease that is caused by an autoimmune response against central nervous system (CNS) structures. Traditionally considered a T-cell-mediated disorder, the contribution of B cells to the pathogenesis of MS has long been debated. Based on recent promising clinical results from CD20-depleting strategies by three therapeutic monoclonal antibodies in clinical phase II and III trials (rituximab, ocrelizumab and ofatumumab), targeting B cells in MS is currently attracting growing interest among basic researchers and clinicians...
January 2017: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/28450894/peginterferon-beta-1a-reduces-disability-worsening-in-relapsing-remitting-multiple-sclerosis-2-year-results-from-advance
#19
Scott D Newsome, Bernd C Kieseier, Shifang Liu, Xiaojun You, Elizabeth Kinter, Serena Hung, Bjoern Sperling
BACKGROUND: In the pivotal phase III 2-year ADVANCE study, subcutaneous peginterferon beta-1a 125 mcg every 2 weeks demonstrated significant improvements in clinical outcomes, including disability endpoints, in patients with relapsing-remitting multiple sclerosis (RRMS). Here, we aim to further evaluate disability data from ADVANCE, and explore associations between confirmed disability progression (CDP), functional status, and health-related quality of life (HRQoL). METHODS: In total, 1512 patients were randomized to placebo or peginterferon beta-1a 125 mcg every 2 or 4 weeks...
January 2017: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/28450893/reliability-and-validity-of-the-attributional-style-questionnaire-survey-in-people-with-multiple-sclerosis
#20
Ian I Kneebone, Sophie J Dewar
BACKGROUND: The current study aimed to examine the psychometric properties of an attributional style measure that can be administered remotely, to people who have multiple sclerosis (MS). METHODS: A total of 495 participants with MS were recruited. Participants completed the Attributional Style Questionnaire-Survey (ASQ-S) and two comparison measures of cognitive variables via postal survey on three occasions, each 12 months apart. Internal reliability, test-retest reliability and congruent validity were considered...
January 2017: Therapeutic Advances in Neurological Disorders
journal
journal
42104
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"